Selected research
Industry Research
Glycogen Synthase Kinase 3 Beta Industry Research Report 2026
Market perspective
The global Glycogen Synthase Kinase 3 Beta market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Glycogen Synthase Kinase 3 Beta is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Glycogen Synthase Kinase 3 Beta is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Glycogen Synthase Kinase 3 Beta is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Glycogen Synthase Kinase 3 Beta include Neurim Pharmaceuticals Ltd, Mitsubishi Tanabe Pharma Corp, Jeil Pharmaceutical Co Ltd, DiaMedica Therapeutics Inc, Angelini Group, AMO Pharma Ltd and Actuate Therapeutics Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Glycogen Synthase Kinase 3 Beta market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Glycogen Synthase Kinase 3 Beta Market by Company
Neurim Pharmaceuticals Ltd
Mitsubishi Tanabe Pharma Corp
Jeil Pharmaceutical Co Ltd
DiaMedica Therapeutics Inc
Angelini Group
AMO Pharma Ltd
Actuate Therapeutics Inc
Glycogen Synthase Kinase 3 Beta Segment by Type
Neu-120
DM-204
AP-1
AP-001
Others
Glycogen Synthase Kinase 3 Beta Segment by Application
Dyskinesia
Musculoskeletal Disorder
Lung Cancer
Menkes Disease
Others
Glycogen Synthase Kinase 3 Beta Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glycogen Synthase Kinase 3 Beta market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Glycogen Synthase Kinase 3 Beta and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glycogen Synthase Kinase 3 Beta.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Glycogen Synthase Kinase 3 Beta manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Glycogen Synthase Kinase 3 Beta by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Glycogen Synthase Kinase 3 Beta in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Neu-120
- DM-204
- AP-1
- AP-001
- Others
Applications
- Dyskinesia
- Musculoskeletal Disorder
- Lung Cancer
- Menkes Disease
- Others
Companies covered
- Neurim Pharmaceuticals Ltd
- Mitsubishi Tanabe Pharma Corp
- Jeil Pharmaceutical Co Ltd
- DiaMedica Therapeutics Inc
- Angelini Group
- AMO Pharma Ltd
- Actuate Therapeutics Inc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Glycogen Synthase Kinase 3 Beta Market Size (2021-2032)
- 2.2.2 Global Glycogen Synthase Kinase 3 Beta Sales (2021-2032)
- 2.2.3 Global Glycogen Synthase Kinase 3 Beta Market Average Price (2021-2032)
- 2.3 Glycogen Synthase Kinase 3 Beta by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Neu-120
- 2.3.3 DM-204
- 2.3.4 AP-1
- 2.3.5 AP-001
- 2.3.6 Others
- 2.4 Glycogen Synthase Kinase 3 Beta by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Dyskinesia
- 2.4.3 Musculoskeletal Disorder
- 2.4.4 Lung Cancer
- 2.4.5 Menkes Disease
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Glycogen Synthase Kinase 3 Beta Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Glycogen Synthase Kinase 3 Beta Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Glycogen Synthase Kinase 3 Beta Revenue of Manufacturers (2021-2026)
- 3.4 Global Glycogen Synthase Kinase 3 Beta Average Price by Manufacturers (2021-2026)
- 3.5 Global Glycogen Synthase Kinase 3 Beta Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Glycogen Synthase Kinase 3 Beta, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Glycogen Synthase Kinase 3 Beta, Product Type & Application
- 3.8 Global Manufacturers of Glycogen Synthase Kinase 3 Beta, Established Date
- 3.9 Global Glycogen Synthase Kinase 3 Beta Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Neurim Pharmaceuticals Ltd
- 4.1.1 Neurim Pharmaceuticals Ltd Company Information
- 4.1.2 Neurim Pharmaceuticals Ltd Business Overview
- 4.1.3 Neurim Pharmaceuticals Ltd Glycogen Synthase Kinase 3 Beta Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Neurim Pharmaceuticals Ltd Glycogen Synthase Kinase 3 Beta Product Portfolio
- 4.1.5 Neurim Pharmaceuticals Ltd Recent Developments
- 4.2 Mitsubishi Tanabe Pharma Corp
- 4.2.1 Mitsubishi Tanabe Pharma Corp Company Information
- 4.2.2 Mitsubishi Tanabe Pharma Corp Business Overview
- 4.2.3 Mitsubishi Tanabe Pharma Corp Glycogen Synthase Kinase 3 Beta Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Mitsubishi Tanabe Pharma Corp Glycogen Synthase Kinase 3 Beta Product Portfolio
- 4.2.5 Mitsubishi Tanabe Pharma Corp Recent Developments
- 4.3 Jeil Pharmaceutical Co Ltd
- 4.3.1 Jeil Pharmaceutical Co Ltd Company Information
- 4.3.2 Jeil Pharmaceutical Co Ltd Business Overview
- 4.3.3 Jeil Pharmaceutical Co Ltd Glycogen Synthase Kinase 3 Beta Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Jeil Pharmaceutical Co Ltd Glycogen Synthase Kinase 3 Beta Product Portfolio
- 4.3.5 Jeil Pharmaceutical Co Ltd Recent Developments
- 4.4 DiaMedica Therapeutics Inc
- 4.4.1 DiaMedica Therapeutics Inc Company Information
- 4.4.2 DiaMedica Therapeutics Inc Business Overview
- 4.4.3 DiaMedica Therapeutics Inc Glycogen Synthase Kinase 3 Beta Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 DiaMedica Therapeutics Inc Glycogen Synthase Kinase 3 Beta Product Portfolio
- 4.4.5 DiaMedica Therapeutics Inc Recent Developments
- 4.5 Angelini Group
- 4.5.1 Angelini Group Company Information
- 4.5.2 Angelini Group Business Overview
- 4.5.3 Angelini Group Glycogen Synthase Kinase 3 Beta Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Angelini Group Glycogen Synthase Kinase 3 Beta Product Portfolio
- 4.5.5 Angelini Group Recent Developments
- 4.6 AMO Pharma Ltd
- 4.6.1 AMO Pharma Ltd Company Information
- 4.6.2 AMO Pharma Ltd Business Overview
- 4.6.3 AMO Pharma Ltd Glycogen Synthase Kinase 3 Beta Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 AMO Pharma Ltd Glycogen Synthase Kinase 3 Beta Product Portfolio
- 4.6.5 AMO Pharma Ltd Recent Developments
- 4.7 Actuate Therapeutics Inc
- 4.7.1 Actuate Therapeutics Inc Company Information
- 4.7.2 Actuate Therapeutics Inc Business Overview
- 4.7.3 Actuate Therapeutics Inc Glycogen Synthase Kinase 3 Beta Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Actuate Therapeutics Inc Glycogen Synthase Kinase 3 Beta Product Portfolio
- 4.7.5 Actuate Therapeutics Inc Recent Developments
5 Global Glycogen Synthase Kinase 3 Beta Market Scenario by Region
- 5.1 Global Glycogen Synthase Kinase 3 Beta Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Glycogen Synthase Kinase 3 Beta Sales by Region: 2021-2032
- 5.2.1 Global Glycogen Synthase Kinase 3 Beta Sales by Region: 2021-2026
- 5.2.2 Global Glycogen Synthase Kinase 3 Beta Sales by Region: 2027-2032
- 5.3 Global Glycogen Synthase Kinase 3 Beta Revenue by Region: 2021-2032
- 5.3.1 Global Glycogen Synthase Kinase 3 Beta Revenue by Region: 2021-2026
- 5.3.2 Global Glycogen Synthase Kinase 3 Beta Revenue by Region: 2027-2032
- 5.4 North America Glycogen Synthase Kinase 3 Beta Market Facts & Figures by Country
- 5.4.1 North America Glycogen Synthase Kinase 3 Beta Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Glycogen Synthase Kinase 3 Beta Sales by Country (2021-2032)
- 5.4.3 North America Glycogen Synthase Kinase 3 Beta Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Glycogen Synthase Kinase 3 Beta Market Facts & Figures by Country
- 5.5.1 Europe Glycogen Synthase Kinase 3 Beta Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Glycogen Synthase Kinase 3 Beta Sales by Country (2021-2032)
- 5.5.3 Europe Glycogen Synthase Kinase 3 Beta Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Glycogen Synthase Kinase 3 Beta Market Facts & Figures by Country
- 5.6.1 Asia Pacific Glycogen Synthase Kinase 3 Beta Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Glycogen Synthase Kinase 3 Beta Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Glycogen Synthase Kinase 3 Beta Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Glycogen Synthase Kinase 3 Beta Market Facts & Figures by Country
- 5.7.1 South America Glycogen Synthase Kinase 3 Beta Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Glycogen Synthase Kinase 3 Beta Sales by Country (2021-2032)
- 5.7.3 South America Glycogen Synthase Kinase 3 Beta Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Glycogen Synthase Kinase 3 Beta Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Glycogen Synthase Kinase 3 Beta Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Glycogen Synthase Kinase 3 Beta Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Glycogen Synthase Kinase 3 Beta Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Glycogen Synthase Kinase 3 Beta Sales by Type (2021-2032)
- 6.1.1 Global Glycogen Synthase Kinase 3 Beta Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Glycogen Synthase Kinase 3 Beta Sales Market Share by Type (2021-2032)
- 6.2 Global Glycogen Synthase Kinase 3 Beta Revenue by Type (2021-2032)
- 6.2.1 Global Glycogen Synthase Kinase 3 Beta Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Glycogen Synthase Kinase 3 Beta Revenue Market Share by Type (2021-2032)
- 6.3 Global Glycogen Synthase Kinase 3 Beta Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Glycogen Synthase Kinase 3 Beta Sales by Application (2021-2032)
- 7.1.1 Global Glycogen Synthase Kinase 3 Beta Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Glycogen Synthase Kinase 3 Beta Sales Market Share by Application (2021-2032)
- 7.2 Global Glycogen Synthase Kinase 3 Beta Revenue by Application (2021-2032)
- 7.2.1 Global Glycogen Synthase Kinase 3 Beta Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Glycogen Synthase Kinase 3 Beta Revenue Market Share by Application (2021-2032)
- 7.3 Global Glycogen Synthase Kinase 3 Beta Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Glycogen Synthase Kinase 3 Beta Value Chain Analysis
- 8.1.1 Glycogen Synthase Kinase 3 Beta Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Glycogen Synthase Kinase 3 Beta Production Mode & Process
- 8.2 Glycogen Synthase Kinase 3 Beta Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Glycogen Synthase Kinase 3 Beta Distributors
- 8.2.3 Glycogen Synthase Kinase 3 Beta Customers
9 Global Glycogen Synthase Kinase 3 Beta Analyzing Market Dynamics
- 9.1 Glycogen Synthase Kinase 3 Beta Industry Trends
- 9.2 Glycogen Synthase Kinase 3 Beta Industry Drivers
- 9.3 Glycogen Synthase Kinase 3 Beta Industry Opportunities and Challenges
- 9.4 Glycogen Synthase Kinase 3 Beta Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst